Receive our newsletter – data, insights and analysis delivered to you
March 1, 2012

Boston introduces Promus Element drug eluting stent in Japan

Boston Scientific has launched its Promus Element everolimus-eluting platinum chromium coronary stent system in Japan.

By admin-demo


Boston Scientific has launched its Promus Element everolimus-eluting platinum chromium coronary stent system in Japan.

The Promus Element stent system features a platinum chromium (PtCr) alloy with an innovative stent design and advanced catheter delivery system, designed to provide improved drug-eluting stent performance for treating patients with coronary artery disease.

The stent system employs a proprietary PtCr alloy designed specifically for coronary stenting, which facilitates improved visibility, less recoil, conformability and higher radial strength.

The system incorporates a low-profile delivery system with a dual-layer balloon and bi-segment inner lumen catheter to provide precise stent delivery across challenging lesions and minimise balloon growth during inflation, for providing high-pressure stent deployment.

Currently, the Promus Element stent is available in a matrix of 74 sizes, ranging in diameter from 2.25mm to 4.00mm and from lengths of 8mm to 32mm on both monorail and over-the-wire catheter platforms. The firm expects that additional 32 mm and 38 mm stent lengths will be available in mid-2012.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Boston Scientific chief executive officer Hank Kucheman said the company provides physicians with a choice of two proven drug and polymer combinations on an innovative coronary stent platform.

Previously, the Platinum Small Vessel study demonstrated safety and efficacy outcomes for the 2.25mm Promus Element stent, including no stent thrombosis or myocardial infarction in treating small vessel coronary disease. The Platinum Long Lesion trial reported low rates of revascularisation while reporting no cardiac death, myocardial infarction or stent thrombosis in patients with long coronary lesions.

The European Commission and the US Food and Drug Administration cleared the Promus Element everolimus-eluting stent system in 2011. Boston Scientific intends to commence commercialising the product immediately in Japan.

The company is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.

Image: Promus Element everolimus-eluting platinum chromium stent system from Boston Scientific has launched in Japan.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy